RecruitingNCT06726226

Extremely Preterm Respiratory Outcome Cohort

Multicenter Cohort for Respiratory Outcome of Preterm Infants


Sponsor

Seoul National University Hospital

Enrollment

600 participants

Start Date

Jun 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This study examines the respiratory outcomes of preterm infants born at gestational ages less than 29 weeks, spanning from birth to 24 months corrected age. It delves into the intricacies of respiratory function impairment attributable to diverse factors, such as respiratory distress syndrome, bronchopulmonary dysplasia, postnatal corticosteroids, ventilatory support, as well as nutritional aspect during NICU stay. Furthermore, it scrutinizes the incidence of chronic respiratory diseases stemming from these conditions, assessing their long-term impact on respiratory prognosis post-discharge. In addition to respiratory aspects, the research extends its focus to the growth and developmental outcomes of preterm infants. By synthesizing these multifaceted elements, the study aspires to enhance current treatments and preventative measures for respiratory conditions in preterm infants.


Eligibility

Max Age: 7 Days

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Standard care for preterm infants for people with infant, premature and respiratory disease. The study is currently recruiting participants at 1 location. People eligible for this study include up to age 7 Days.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERStandard care for preterm infants

Standard care for preterm infants according to the institutional protocol


Locations(1)

Seung Han Shin

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06726226


Related Trials